Principal Investigator: David Guay / Feldan Therapeutics Co-Investigators: Frédéric Couture / TransBio Tech Project of $1,363,590 over 2 years Supported by CQDM through: Ministère de l’Économie, de l’Innovation et de l’Énergie du Québec (MEIE) And by co-funding partners: Feldan Therapeutics, Amgen Canada The project in details: Challenge: Lung diseases are one of the leading causes…
Principal Investigator: Nathalie Johnson / Jewish General Hospital Co-Investigators: N/A Project of $583,800 over 3 years Supported by CQDM through: Ministère de l’Économie, de l’Innovation et de l’Énergie du Québec (MEIE) And by co-funding partners: Hoffman-La Roche, JGH Foundation The project in details: Challenge: Diffuse large B cells lymphoma (DLBCL) is the most common lymphoma…
CQDM celebrates its 15th anniversary with encouraging messages from its partners and founders: -Pierre Fitzgibbon, Quebec Minister of Economy, Innovation and Energy (MEIE) -Diane Gosselin, CEO of CQDM -Rémi Quirion, Chief Scientist of Quebec -Max Fehlmann, Founder CQDM -Jennifer Chan, MERCK Canada -Vratislav Hadrava, Pfizer Canada A big thank you for your contributions and for…
ABOUT CQDMCQDM is a biopharmaceutical research consortium whose mission is to fund the development of innovative tools and technologies that accelerate the development of safe and effective drugs. We bring together world-leading pharmaceutical organizations, several Canadian biotech companies, the best researchers from the public and private sectors, as well as the Canadian and Québec governments.…
CQDM and Neurenati Therapeutics Fund the Development of an Innovative Treatment against Hirschsprung Disease Montreal, February 29, 2024 – On this International Rare Disease Day, CQDM is proud to announce the funding of a collaborative research project aimed to develop a revolutionary therapeutical approach for Hirschsprung disease. This project with a total value of over…
CQDM Supports the Development of Three Promising Innovations in the Fight Against Cancer with Biopharmaceutical Companies Theratechnologies, Saydi Biotech and Roche. Montreal, February 4, 2024 – On this World Cancer Day, CQDM is proud to contribute to the fight against this global scourge by announcing the funding of three R&D projects made possible thanks to…
Challenge: The storage and worldwide distribution of vaccines represent complex issues for pharmaceutical companies due to vaccine instability at ambient temperatures. Spray drying is an established industrial processing technology for stabilizing many products as dried powders. Although studies have shown spray drying to be promising for preparing thermally stable vaccines in order to alleviate cold…
Challenge: The most critical step in discovering future medications is the identification of the initial hit compounds (“leads”) that interact with target proteins, and which have the desired properties. The search for and validation of potential lead compounds is a major challenge for launching drug discovery programs as this process requires highly specialized expertise, expensive equipment…
Challenge: Cancers with metastases are responsible for 90% of cancer deaths. Unfortunately, metastases often become refractory to treatment and although certain molecules are theoretically able to act on these tumors, their non-targeted administration greatly limits their effectiveness. Solution: This project aims to validate the efficacy of the peptide-drug (TH1902) on secondary tumors by characterizing its mechanisms of…
Challenge: Despite improvements in the treatment of many pediatric cancers, high-risk subtypes such as acute myeloid leukemia (AML) and acute megakrayoblastic leukemia (AMKL) still have amongst the worst prognosis, with only ~40-60% survival at 5-years. There is therefore a critical unmet medical need for novel targeted treatments but to completely eradicate the tumor cells these treatments…